Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ABT - Abbott Labs -- Ignore unavailable to you. Want to Upgrade?

To: Angel D who wrote (247)	10/10/1999 7:26:00 PM
From: Angel D	Read Replies (1) \| Respond to of 328

ASA ATTENDEES Welcome to the Yahoo BioTime message board. You clearly have learned something about Hextend at the ASA Annual Meeting. Links provided below will direct you to additional information. The purpose of this message is to introduce you to BioTime, Inc. (BTX-AMEX), the company which created Hextend and licenses it to Abbott. BIOTIME, INC. BioTime was founded in Berkeley in 1990 to research and develop plasma expanders, blood volume substitutes and organ preservation solutions for use in surgery, trauma care and organ transplant procedures. The company has 13 employees and expenses of about $6 million per year. BTX carries no debt and has more than $7 million in the bank. The first royalty check from Abbott for the sale of Hextend will arrive this quarter. BioTime has 10.9 million shares outstanding and a float of 7.4 million shares. BTX also has a short interest of more than 2.5 million shares. This huge short interest is a major part of the BTX story. PRODUCTS BioTime has more than a dozen patents for Hextend and its other products. FDA approval for Hextend was granted last March, exactly one year after completing the application. An application for Canadian approval was filed in July and BioTime is working on regulatory approvals in Europe and Japan. The company has at least 3 additional products in its pipeline - Pentalyte, Hetacool and Hetafreeze. INDs for Pentalyte and Hetacool are expected to be filed this year. These products are described at: biotimeinc.com ABBOTT AGREEMENT BioTime's agreement with Abbott will pay the company a sliding scale royalty of up to 36% of net annual sales. In addition to the royalty, Abbott will pay a licensing fee of up to$37,500,000. The Abbott agreement covers the US and Canada and includes the option to acquire rights to other products in BioTime's pipeline. The full agreement can be viewed at: sec.gov . BTX is negotiating similar agreements with major overseas pharmaceutical companies. By the Abbott agreement, Hextend sales of $50 million per year will generate revenues of about $.75 per share for BTX shareholders. Sales of $100 million will generate about $3.00 in revenue and $200 million would generate about $8.00. Expenses currently run about $.55 per share. P/Es for profitable biotech companies average more than 40 times earnings. The total US market for plasma volume expanders is in excess of $400 million. The global market has been estimated at more than $1.0 billion. SHORTS A large short position was established in BioTime years ago by a few individuals who believed that Hextend was snake oil. However, in 1998 with Hextend's NDA filing, the announcement of the Abbott deal and a move to the NASDAQ, it became clear that they had made a mistake. They immediately began an aggressive campaign to undermine the stock by issuing misleading press releases, shilling message boards and (with their substantial influence on the float) by outright manipulation of the stock. While they have successfully kept a lid on BTX so far, the price they have paid is a substantial increase the size of the short position. nasdaq-amex.com . But now that sales and revenues are beginning, the shorts are faced with a terrifying prospect - a short squeeze of historic proportions. INVESTING If you decide to invest in BTX, the large short position makes it is VERY important that you buy in a Type 1 Cash Account and that you not purchase BTX in a margin account. A more thorough discussion of BioTime, Hextend, shorts sellers and Type 1 Accounts can be viewed in 5 sequential posts beginning with the link below. messages.yahoo.com . You can also call Ron Barkin, BioTime President, at 510 845-9535.

To: Angel D who wrote (247)	11/25/1999 5:13:00 AM
From: Charles Broderick	Respond to of 328

Abbott may have to share the remains of the TURKEY in Thanksgiving....but why worry, if BII does'nt get taken over by abbott their $!!mil dollar loan is convertible at $4 by which time the value of the loan may be $16 or more. I hope that from tomorrow, with THANKSGIVING over, we will be seeing the share price start to REALLY move........... The share has several key components that all of us should be aware of, as this price is extremely FALSE and undervalued....... Let's examine why? 1.Last Year, Johnson & Johnson and BII talked all the way to œ14 without striking a deal, based on JnJ's interest then in BII's UNAPPROVED stent product(holds open arteries in surgery...only two other makers in the world). 2.Merrill Lynch six months ago issued a strong buy with a price target of œ2.60, updating it in the light of recent events to nearer œ6. 3.Boston Scientific and Abbott start getting interested. Pause for a moment and take this on board!! The CORE of their interest, all three, is that they could'nt give a toss for BII's product outside the USA, they were-are, only interested in the product, and possibly the company, in the context of a Federal Drug Administration Agency approved product for the USA markets. That is the CENTRAL issue. Read on! 4.Abbott, sensing that BII are near to FAST TRACKING the stents through the FDA, give BII an UNSECURED loan of œ7 mil...to buy out the 40% of product rights they dont own from another American partner in the product. Well, they did get a bit of security, i.e. the right to convert the loan at "wait for it" yep, you got it...œ2.60. 5. The share price starts to go mad, and all the Newspapers, and I mean ALL, reccommend it even naming prices, from œ4.90 thru œ6 within days......Did'nt happen yet. 6. Nomura issue a BUY rating 7. Killinick, followed by others........ 8. Saloman Smith Barney issue a BUY yesterday........price went down. WHY????????? To let the INSTITUTIONS in before the BIG DAY!!!!!! It never ceases to happen....you and me dont count.....before the IT happens a stock's price always goes back 20% or so from recent highs to give the institutions their fill....THAT IS NOT A STATEMENT OF FACT,SIMPLY MY OPINION.... What is the IT>>>>>>>>>>>>>>>>>>> Tjhis share is all about STENTS, andnothing to do with analysts reccommendations, and nothing to do with the very impressive FINANCIALS last week.... IT is all about........FEDERAL DRUG ADMINISTRATION AGENCY approval!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! If that happens, we will see the PREMPTIVE strike made by ABBOTT, with their œ7 million, convertibles, turned into a dogfight between J & J, Boston (been smarting for two years at failing to get BII, just read shareholder comments on YAHOO 2 months ago...BSX), and if ABBOTT dont get the deal ultimately, they have œ7 million pounds convertible at œ2.60 which will yield enough profit to cover their anticipated share losses for 1999. Target..œ6 plus certainly.....Sell half your holding and hold for more..... Chances of Fda approval....................10/1 on!!! DONT SELL AT THESE PRICES!!!!!!!!!! The purpose of the ADMIRE list is to generate interest and discussion in equities. It is not in any way a placing memorandum or offer document or a treaty or invitation to purchase or acquire equities. Members should always obtain their own independent financial advice. The information in the ADMIRE list is confidential and proprietary and is intended only for the persons to whom it is transmitted. Receipt or possession of information does not convey any rights to disclose its contents in whole or in part to any third party. The ADMIRE list does not constitute an offer to sell or purchase any securities. Opinions expressed within the ADMIRE list are personal opinions of its members and are NOT to be relied upon as accurate. It must be understood that projections and predictions about a company's future performance are necessarily subject to a high degree of uncertainty, and no warranty is expressed or implied herein. Any persons considering making an investment on the basis of information contained in the ADMIRE list are urged to make their own enquiries and to form their own opinions on the company and its prospects. And if necessary, to seek professional advice. Investment in certain quoted companies involves a high degree of risk. An investment should only be considered by those persons who could sustain a loss on their investment.